In the 6 years since the introduction of the first commercial immunoassays for prostate-specific antigen (PSA), this unique tissue-specific antigen has become established as the most useful serological marker for monitoring patients with prostate cancer. The antigen was originally isolated from semen by three independent laboratories searching for semen-specific antigens (1) (2) (3) . Later, at Roswell Park Institute, the antigen was purified from normal prostate tissue, its natural source (4). This research group pioneered the use of PSA as a tumor marker to monitor patients with prostate cancer (5).
Subsequent experience has shown that PSA is considerably more useful than prostatic acid phosphatase to monitor prostate cancer (6, 7) . Serum concentrations of PSA correlate strongly with the volume and clinical stage of prostate cancer. After radical prostatectomy for localized cancer (stages A and B), serum PSA falls to amounts that are undetectable by the current generation of immunoassays for PSA (7) . Serially increasing concentrations of PSA above the limits of detection of current tests appear to be the earliest sign of residual cancer (7-11). Many physicians no longer use prostatic acid phosphatase to routinely monitor their cancer patients, although rare cases of patients with metastatic prostate cancer and normal PSA concentrations have been published (12).
More recently, PSA has been recommended as an important adjunct to a careful digital rectal examination to screen men over age 50 years for prostate cancer (13) (14) (15) 
